Pharmacotherapy of nonalcoholic steatohepatitis: reflections on the existing evidence

Abstract Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not been approved so far by the US Food and Drug Administration (FDA). Over the past decade, a large number of clinical studies have explored the safety and efficacy of different drugs in the treatment of nonalcoholic steatohepatitis (NASH). Diet pills, antioxidants, insulin sensitizers, lipid‐lowering agents, anti‐inflammatory cytokines, cytoprotective agents, and intestinal probiotics are some of the drugs that have been investigated by different groups. Based on the evidence from randomized clinical trials (RCTs), a number of academic groups have developed guidelines for the diagnosis and management of NAFLD and NASH. In this paper, we discussed the current situation of NASH pharmacotherapy.
Source: Journal of Digestive Diseases - Category: Gastroenterology Authors: Tags: Leading article Source Type: research